Literature DB >> 21357790

Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.

Tomasz Szczepanski1, Vincent H J van der Velden, Esmé Waanders, Roland P Kuiper, Pieter Van Vlierberghe, Bernd Gruhn, Cornelia Eckert, Renate Panzer-Grümayer, Giuseppe Basso, Hélène Cavé, Udo Zur Stadt, Dario Campana, André Schrauder, Rosemary Sutton, Elisabeth van Wering, Jules P P Meijerink, Jacques J M van Dongen.   

Abstract

PURPOSE: Relapse of childhood T-cell acute lymphoblastic leukemia (T-ALL) often occurs during treatment, but in some cases, leukemia re-emerges off therapy. On the basis of previous analyses of T-cell receptor (TCR) gene rearrangement patterns, we hypothesized that some late recurrences of T-ALL might in fact represent second leukemias. PATIENTS AND METHODS: In 22 patients with T-ALL who had late relapses (at least 2.5 years from diagnosis), we studied TCR gene rearrangement status at first and second presentation, NOTCH1 gene mutations, and the presence of the SIL-TAL1 gene fusion. We performed genome-wide copy number and homozygosity analysis by using oligonucleotide- and single nucleotide polymorphism (SNP) -based arrays.
RESULTS: We found evidence of a common clonal origin between diagnosis and relapse in 14 patients (64%). This was based on concordant TCR gene rearrangements (12 patients) or concordant genetic aberrations, as revealed by genome-wide copy number analysis (two patients). In the remaining eight patients (36%), TCR gene rearrangement sequences had completely changed between diagnosis and relapse, and gene copy number analysis showed markedly different patterns of genomic aberrations, suggesting a second T-ALL rather than a resurgence of the original clone. Moreover, NOTCH1 mutation patterns were different at diagnosis and relapse in five of these eight patients. In one patient with a second T-ALL, SNP analysis revealed a germline del(11)(p12;p13), a known recurrent aberration in T-ALL.
CONCLUSION: More than one third of late T-ALL recurrences are, in fact, second leukemias. Germline genetic abnormalities might contribute to the susceptibility of some patients to develop T-ALL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357790     DOI: 10.1200/JCO.2010.30.2877

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

Review 1.  Genomic profiling of B-progenitor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-06       Impact factor: 3.020

2.  Hematology: Late relapse or new disease?

Authors:  M Teresa Villanueva
Journal:  Nat Rev Clin Oncol       Date:  2011-05       Impact factor: 66.675

Review 3.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

4.  Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Authors:  E Waanders; B Scheijen; M C J Jongmans; H Venselaar; S V van Reijmersdal; A H A van Dijk; A Pastorczak; R D A Weren; C E van der Schoot; M van de Vorst; E Sonneveld; N Hoogerbrugge; V H J van der Velden; B Gruhn; P M Hoogerbrugge; J J M van Dongen; A Geurts van Kessel; F N van Leeuwen; R P Kuiper
Journal:  Leukemia       Date:  2016-10-13       Impact factor: 11.528

5.  End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Chintan Parekh; Paul S Gaynon; Hisham Abdel-Azim
Journal:  Pediatr Blood Cancer       Date:  2015-05-14       Impact factor: 3.167

6.  Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.

Authors:  Joachim B Kunz; Tobias Rausch; Obul R Bandapalli; Juliane Eilers; Paulina Pechanska; Stephanie Schuessele; Yassen Assenov; Adrian M Stütz; Renate Kirschner-Schwabe; Jana Hof; Cornelia Eckert; Arend von Stackelberg; Martin Schrappe; Martin Stanulla; Rolf Koehler; Smadar Avigad; Sarah Elitzur; Rupert Handgretinger; Vladimir Benes; Joachim Weischenfeldt; Jan O Korbel; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 7.  Molecular genetics of B-precursor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  The TCR γδ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant Vδ1 and Vδ2 T cells.

Authors:  Haitao Zheng; Xu Wang; Yu Ma; Bing Xu; Shaohua Chen; Lijian Yang; Xiuli Wu; Grzegorz K Przybylski; Suming Huang; Tiezhen Ye; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2013-12-13       Impact factor: 3.311

9.  Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic.

Authors:  Charles G Mullighan; Cheryl L Willman
Journal:  J Adolesc Young Adult Oncol       Date:  2011-06       Impact factor: 2.223

10.  Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.

Authors:  Kjeld Schmiegelow; Mette Frandsen Levinsen; Andishe Attarbaschi; Andre Baruchel; Meenakshi Devidas; Gabriele Escherich; Brenda Gibson; Christiane Heydrich; Keizo Horibe; Yasushi Ishida; Der-Cherng Liang; Franco Locatelli; Gérard Michel; Rob Pieters; Caroline Piette; Ching-Hon Pui; Susana Raimondi; Lewis Silverman; Martin Stanulla; Batia Stark; Naomi Winick; Maria Grazia Valsecchi
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.